Key Takeaways AbbVie expects 2026 oncology sales of $6.5 billion, down from 2025 due to lower Imbruvica pricing.Newer drugs like Epkinly, Elahere and Emrelis are driving growth, offsetting Imbruvica declines.AbbVie is advancing ADCs and pipeline candidates to strengthen its oncology portfolio.AbbVie (ABBV) has built a significant presence in the oncology space. While the majority of the revenues are generated from blood cancer drugs Imbruvica and Venclexta, the company has diversified its offerings with new ...

Key Takeaways AbbVie fell below its 50-day SMA, hinting at short-term weakness, but remains above 200-day trendSkyrizi and Rinvoq drove growth with $26B sales in 2025, expected to exceed $31B in 2026Humira erosion and weak aesthetics sales persist, but pipeline, M&A, and new drugs support growthAbbVie (ABBV) stock slipped below its 50-day simple moving average (SMA) on March 13, after consistently trading above it since mid-Feb. However, the stock has remained comfortably above its 200-day SMA for more than ...

Core Viewpoint - AbbVie reported strong fourth-quarter earnings, with adjusted EPS and revenues exceeding expectations, driven by robust sales of key drugs, although facing challenges from Humira's generic erosion and declining sales in certain segments [2][3][7]. Financial Performance - Fourth-quarter 2025 adjusted EPS was $2.71, beating the Zacks Consensus Estimate of $2.66 and the company's guidance of $2.61-$2.65, with earnings rising over 25% year over year [2]. - Revenues reached $16.62 billion, surpassing the Zacks Consensus Estimate of $16.36 billion and the company's guidance of $16.3 billion, reflecting a 10% year-over-year increase [2]. - Full-year 2025 sales rose 8.6% to $61.16 billion, exceeding the Zacks Consensus Estimate of $60.93 billion [21]. Drug Performance - Key drugs such as Rinvoq, Skyrizi, Venclexta, and Vraylar contributed significantly to revenue growth, while Humira faced a 26% sales decline due to biosimilar competition [3][7]. - Skyrizi sales were $5.01 billion, up 31.9% year over year, while Rinvoq sales reached $2.37 billion, up nearly 28.6% [4][5]. - AbbVie's ex-Humira drugs saw a 14.5% increase in sales, driven by strong performance in immunology and neuroscience [3]. Future Outlook - For 2026, AbbVie expects total revenues of $67 billion, representing a growth of approximately 9.5%, driven by Skyrizi and Rinvoq sales, alongside a substantial ramp for Vyalev [22]. - The company anticipates adjusted EPS in the range of $14.37-$14.57 for 2026, excluding impacts from acquired IPR&D expenses [22]. - Global immunology sales are projected to reach $34.5 billion in 2026, with Skyrizi and Rinvoq expected to generate significant revenue [8]. Cost and Margin Analysis - Adjusted gross margin was 83.6% in the quarter, with adjusted SG&A expenses rising 4% year over year to $3.71 billion [20]. - Adjusted operating margin was 38.3%, reflecting a 7.6% unfavorable impact from acquired IPR&D expenses [20]. Market Position and Competitors - AbbVie holds a Zacks Rank 3 (Hold), indicating an expectation of in-line returns in the coming months [29]. - The company is positioned within the Zacks Large Cap Pharmaceuticals industry, where competitors like Pfizer have also reported mixed results [30].

Core Insights - AbbVie reported better-than-expected fourth-quarter results but faced stock price pressure due to declining oncology drug sales and market caution regarding growth sustainability [1] - The company has successfully launched new drugs, Skyrizi and Rinvoq, to offset the decline from Humira, which lost patent protection [2][3] - AbbVie expects continued revenue growth driven by strong performance in immunology and neuroscience, despite challenges in aesthetics and oncology segments [9][23] Group 1: Financial Performance - AbbVie achieved combined sales of Skyrizi and Rinvoq of $26 billion in 2025, representing over 40% year-over-year growth, with projections of over $31 billion for 2026 [3][9] - The company anticipates a revenue growth of approximately 9.5% in 2026, driven by Skyrizi, Rinvoq, and Vyalev, while facing headwinds from Humira erosion [23][24] - AbbVie's neuroscience drugs generated nearly $10.8 billion in sales in 2025, marking a 20% increase, supported by products like Botox Therapeutic and Vraylar [6] Group 2: Product Pipeline and Growth Drivers - AbbVie is focusing on expanding its immunology portfolio with potential new indications for Rinvoq, which could add approximately $2 billion to peak-year sales [4] - The oncology segment generated $6.6 billion in 2025, with new drugs like Elahere and Epkinly contributing to revenue despite a decline in Imbruvica sales [8][10] - AbbVie has been actively acquiring innovative pipeline candidates, investing over $5 billion in 2025 to enhance its early-stage pipeline [11] Group 3: Challenges and Market Conditions - Humira sales are declining significantly due to biosimilar competition, with a projected 50% drop in 2025 and continued erosion expected in 2026 [12] - The aesthetics segment is facing challenges, with global sales declining 5.9% in 2025, and expectations for flat growth in 2026 [13][14] - AbbVie is navigating competitive pressures in its oncology portfolio, but remains optimistic about its pipeline and future product approvals [10][23] Group 4: Stock Valuation and Market Position - AbbVie stock has risen 17.9% over the past year, slightly underperforming the industry average of 19.5% [15][16] - The stock is trading at a price/earnings ratio of 15.75, which is lower than the industry average of 18.83, indicating reasonable valuation [18] - The Zacks Consensus Estimate for 2026 earnings has increased slightly from $14.45 to $14.49 per share, reflecting positive sentiment [20]

Core Insights - AbbVie experienced a sales growth of approximately 8.5% year over year in 2025, despite facing biosimilar erosion of its flagship drug Humira, which lost exclusivity in early 2023 [2] - For 2026, AbbVie projects revenues to reach $67 billion, indicating a growth of about 9.5% over 2025, primarily driven by newer immunology drugs Rinvoq and Skyrizi [3][10] Immunology Segment - AbbVie expects to generate over $31 billion from sales of Skyrizi and Rinvoq in 2026, with both drugs anticipated to grow more than 20% year over year [4][5][10] - Skyrizi is projected to achieve sales of approximately $21.5 billion, while Rinvoq is expected to reach around $10.1 billion [5] Neuroscience Segment - The neuroscience franchise is expected to contribute $12.5 billion in sales for 2026, reflecting a 16% growth over 2025 [7][10] - AbbVie anticipates Vyalev, a new Parkinson's disease therapy, to surpass $1 billion in global sales [7][10] - The company is also seeking FDA approval for a new oral therapy for Parkinson's disease, tavapadon, which could further enhance its neuroscience portfolio [8] Oncology Segment - AbbVie faces near-term challenges in its oncology segment, particularly with the J&J-partnered Imbruvica, which is expected to see sales decline to $2.2 billion, a drop of over 23% from 2025 [11][12][10] - Despite this decline, other oncology drugs are expected to partially offset the impact, including Venclexta, Epkinly, Elahere, and Emrelis [12] Valuation and Market Performance - AbbVie shares have underperformed the industry over the past year and are currently trading at a P/E ratio of 15.25, below the industry average of 18.75 [13][14] - The bottom-line estimate per share for 2026 and 2027 has seen a decline in the past 30 days [16]

Core Viewpoint - AbbVie Inc. is a leading biopharmaceutical company with strong financial performance in Q4 2025, driven by its immunology portfolio, and is projected to exceed profit expectations for 2026 [1][2][6] Financial Performance - AbbVie reported Q4 2025 sales of $16.62 billion, exceeding the consensus estimate of $16.42 billion, marking a 10% increase on a reported basis and a 9.5% increase operationally [2] - Adjusted earnings per share rose by 25.5% to $2.71, surpassing the expected $2.65 [2] Revenue Breakdown - The immunology portfolio generated global net revenues of $8.63 billion, reflecting an 18.3% increase, with Skyrizi sales up 32.5% to $5.01 billion and Rinvoq sales rising 29.5% to $2.37 billion [3] - Neuroscience sales climbed to $2.96 billion, a 17.9% increase, with Vraylar contributing $1.02 billion (up 10.5%) and Botox Therapeutics at $991 million (up 13.4%) [4] - The oncology portfolio saw a slight decline, generating $1.66 billion in sales, with Imbruvica's revenues down 20.8% to $671 million, while Venclexta's revenues increased by 8.6% to $711 million [4] Future Projections - AbbVie projects its 2026 profit to surpass Wall Street estimates, driven by strong sales of Skyrizi and Rinvoq [5][6] - The current stock price of ABBV is $216.97, reflecting a decrease of 3.85% or $8.69, with a market capitalization of approximately $383.47 billion [5]

Core Insights - AbbVie Inc. reported fourth-quarter earnings and revenue that surpassed Wall Street expectations, driven by strong performance in its immunology and neuroscience segments, although shares fell over 2% in premarket trading after the announcement [1] Financial Performance - The company posted adjusted earnings per share of $2.71 for the quarter, exceeding the consensus estimate of $2.65 [2] - Revenue reached $16.62 billion, surpassing analyst expectations of $16.39 billion, reflecting a year-over-year growth of 10.0%, or 9.5% on an operational basis [2] Segment Performance - Immunology was the main growth driver, with global net revenues increasing by 18.3% to $8.63 billion [3] - Skyrizi generated $5.01 billion in sales, marking a 32.5% increase from the previous year, while Rinvoq contributed $2.37 billion, representing a growth of 29.5% [3] - Sales of Humira declined by 25.9% to $1.25 billion due to biosimilar competition, but the gains in Skyrizi and Rinvoq offset this decline [3] - The neuroscience portfolio also performed well, with revenue rising 17.9% to $2.96 billion [4] - Vraylar sales increased by 10.5% to $1.02 billion, and Botox Therapeutic revenue advanced by 13.4% to $990 million [4] - The oncology portfolio saw a slight decline of 1.5% to $1.66 billion, primarily due to a 20.8% drop in Imbruvica sales, although growth in Venclexta and Elahere partially offset this [4] Future Guidance - AbbVie provided full-year 2026 adjusted earnings guidance of $14.37 to $14.57 per share, which is above the analyst consensus of $14.22 [5]

Core Insights - AbbVie Inc. reported fourth-quarter 2025 adjusted EPS of $2.71, surpassing the Zacks Consensus Estimate of $2.66 and the company's prior guidance of $2.61-$2.65, with earnings increasing over 25% year over year [1][10] - The company's revenues reached $16.62 billion, exceeding the Zacks Consensus Estimate of $16.36 billion, with a year-over-year growth of 10.0% on a reported basis and 9.5% operationally [2][10] Revenue Performance - Key drugs driving revenue included Rinvoq, Skyrizi, Venclexta, and Vraylar, alongside contributions from newer drugs like Ubrelvy, Qulipta, Elahere, and Vyalev, while sales of Humira and Imbruvica declined [3] - Immunology drug Rinvoq generated $2.37 billion in net revenues, up nearly 29%, although it missed the Zacks Consensus Estimate of $2.39 billion [4] - Skyrizi's sales reached $5.01 billion, reflecting a 32% increase and surpassing the Zacks Consensus Estimate of $4.91 billion [5] - Humira's sales fell 26% to $1.25 billion, with U.S. sales down 28% to $897 million, attributed to loss of exclusivity since January 2023, yet it exceeded the Zacks Consensus Estimate of $949 million [6] - Neuroscience portfolio sales rose over 17% to $2.96 billion, driven by Botox Therapeutic and Vraylar, but missed the Zacks Consensus Estimate of $3.00 billion [7] - Oncology franchise sales decreased 2.5% to $1.66 billion, primarily due to declining Imbruvica sales, missing the Zacks Consensus Estimate of $1.72 billion [9] Cost and Financial Outlook - Adjusted SG&A expenses increased 4% year over year to $3.71 billion, while adjusted R&D expenses rose approximately 13% to $2.56 billion [15] - For the full year 2025, AbbVie reported sales growth of 8.6% to $61.16 billion, exceeding the Zacks Consensus Estimate of $60.93 billion, with adjusted EPS of $10.00, down 1% year over year but beating estimates [16] - AbbVie provided guidance for 2026 adjusted EPS in the range of $14.37-$14.57, excluding impacts from proposed acquisitions, with the Zacks Consensus Estimate at $14.32 [17] Market Reaction and Strategic Focus - Despite strong results, AbbVie's shares traded lower in pre-market trading, likely due to underperformance in Rinvoq and oncology drugs [19] - The company is focusing on inorganic growth to strengthen its early-stage pipeline across multiple therapeutic areas, with recent acquisitions impacting near-term earnings [21][22]

Core Insights - AbbVie Inc. reported fourth-quarter 2025 sales of $16.62 billion, exceeding the consensus estimate of $16.42 billion, with a 10% increase on a reported basis and 9.5% on an operational basis [1] - Adjusted earnings per share were $2.71, up 25.5%, surpassing the consensus of $2.65 [1] Immunology Portfolio - Global net revenues from the immunology portfolio reached $8.63 billion, an increase of 18.3% (+17.7% operationally) [2] - Skyrizi sales increased by 32.5% to $5.01 billion, Rinvoq sales rose by 29.5% to $2.37 billion, while Humira sales declined by 25.9% to $1.25 billion [2] Neuroscience Portfolio - Neuroscience portfolio sales totaled $2.96 billion, up 17.9% [2] - Vraylar net revenues were $1.02 billion, reflecting a 10.5% increase, and Botox Therapeutics generated $991 million, up 13.4% [2] Oncology Portfolio - The oncology portfolio generated sales of $1.66 billion, down 1.5% [3] - Imbruvica's net revenues were $671 million, down 20.8%, while Venclexta's revenues increased by 8.6% to $711 million, and Elahere's revenues were $182 million [3] Cosmetic Products - Global Botox Cosmetic net revenues were $717 million, up 4.2%, while Juvederm net revenues decreased by 10.7% to $249 million [3] Financial Metrics - The adjusted gross margin ratio was reported at 83.6% [3] Guidance - AbbVie provided fiscal 2026 adjusted earnings guidance of $14.37-$14.57 per share, compared to the consensus of $14.24 [4] Market Reaction - AbbVie shares experienced a decline of 6.70%, trading at $210.53 at the time of publication [5]

Core Insights - AbbVie reported revenue of $16.62 billion for the quarter ended December 2025, reflecting a 10% increase year-over-year and a surprise of +1.58% over the Zacks Consensus Estimate of $16.36 billion [1] - The earnings per share (EPS) for the quarter was $2.71, up from $2.16 in the same quarter last year, with an EPS surprise of +2.02% compared to the consensus estimate of $2.66 [1] Revenue Performance by Product - Humira's net revenue in the US was $897 million, significantly below the average estimate of $574.85 million, representing a year-over-year decline of -28% [4] - Internationally, Humira generated $349 million, slightly below the estimated $374.4 million, marking a -20% change year-over-year [4] - Oncology product Elahere reported $182 million, which was below the average estimate of $191.62 million but showed a +23% increase year-over-year [4] - Qulipta's international revenue reached $43 million, exceeding the estimate of $39.74 million, with a remarkable +186.7% year-over-year growth [4] - The Juvederm Collection generated $249 million, below the estimate of $272.17 million, reflecting a -10.8% year-over-year decline [4] - Vraylar's total revenue was $1.02 billion, surpassing the estimate of $994.67 million, with a +10.6% year-over-year increase [4] - Imbruvica's revenue was $671 million, below the average estimate of $714.9 million, showing a -20.9% year-over-year decline [4] - Eye Care products generated $580 million, slightly above the estimate of $568.88 million, with a -10.2% year-over-year change [4] - Botox Therapeutic revenue was $990 million, close to the estimate of $995.91 million, reflecting a +13.4% year-over-year increase [4] - Aesthetics revenue totaled $1.29 billion, slightly above the estimate of $1.28 billion, with a -0.9% year-over-year change [4] - Venclexta generated $710 million, below the estimate of $725.34 million, with an +8.4% year-over-year increase [4] - Neuroscience product Vyalev reported $183 million, exceeding the estimate of $170.15 million [4] Stock Performance - AbbVie shares returned +0.8% over the past month, compared to a +0.9% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]